Back to List View Graph View

Fenofibrate

Fenofibrate is a synthetic lipid-modifying agent in the fibrate class, used clinically to lower elevated triglycerides and, in some settings, to improve mixed dyslipidemia.

Where the papers sit

10 papers from the last 6 months study fenofibrate directly · updated from PubMed 11 Nov 2026

Study type 0 clinical trials · 3 observational · 6 preclinical · 1 unclassified

Themes 3 themes · 1 new direction

  • Drug Formulation and Analysis

    Solubility enhancement and controlled delivery are the main aims, with cyclodextrin electrospun inserts and nanoemulsion redistribution used to improve fenofibrate exposure. HPLC and UHPLC assays support tablet quality assessment, while NMR quantifies drug movement during formulation destabilization. The work remains predominantly pharmaceutical-development and analytical rather than clinical. Safety data for pemafibrate broaden the cluster toward post-market risk assessment without establishing a single preferred formulation.

    5 papers · 50%

  • Long-Term Clinical Outcomes

    Fenofibrate research is moving beyond lipid measurements toward long-term clinical outcomes in high-risk disease. Prolonged therapy after hypertriglyceridemic pancreatitis is assessed for recurrence or safety, while add-on treatment in primary biliary cholangitis is linked to transplant-free survival. Real-world diabetes data examine sight-threatening retinopathy, extending interest to microvascular protection. Retrospective cohorts, follow-up and adjusted hazard models dominate, leaving causality and comparative effectiveness unresolved.

    3 papers · 30%

  • Others — Inflammation and Triglyceride Disorders

    Hypertriglyceridemia-induced pancreatitis is addressed clinically with fenofibrate and plasmapheresis, while a separate computational study links sepsis to cell-senescence genes and candidate drugs. No shared mechanism or clinical endpoint connects these strands. The pancreatitis case supports acute triglyceride control in pregnancy, but it is single-patient evidence. The sepsis analysis remains hypothesis-generating, so the cluster has no clear therapeutic direction.

    2 papers · 20%

NEW DIRECTION

Fenofibrate is repositioned as a candidate therapy for sepsis-associated cellular senescence

The sepsis study using bioinformatics, machine learning, and in vivo and in vitro models treats fenofibrate not as a lipid-lowering intervention or formulation target, but as a potential drug directed at senescence-related molecular abnormalities in sepsis. The study instead identifies fenofibrate through interactions with sepsis-associated hub proteins, including CDKN1C, BCL2, and SMAD3, giving it a proposed role in cellular-senescence-driven organ dysfunction rather than the lipid disorders and drug-delivery problems addressed elsewhere in the set. This expands fenofibrate into a senescence-targeted sepsis research direction, although the abstract does not establish clinical efficacy 42219284May.

fenofibrate chemical structure

Papers

The 10 papers from the last 6 months that study fenofibrate directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Drug Formulation and Analysis (5)
  1. Dissolution Enhancement by Binding Agents: A Potential Shortcut to Improving Bioavailability? The AAPS journal · 10 Sept 2026 PMID 42717179
  2. Polymer-free electrospun hydroxypropyl-β-cyclodextrin inserts for sustained ocular delivery of fenofibrate: a novel approach for management of posterior segment ocular disease. International journal of pharmaceutics · 28 Aug 2026 PMID 42665196
  3. Development and Validation of Isocratic RP-UHPLC Method for Assay of Fenofibrate Tablet. Biomedical chromatography : BMC · 28 Jul 2026 PMID 42517867
  4. Data Mining of the Japanese Adverse Drug Event Report Database and Animal Experiments for Assessment of Risks Associated With Pemafibrate. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379788
  5. Visualizing the Spatiotemporal Redistribution of Drugs in Destabilizing Nanoemulsions: A Quantitative Solution 1H NMR Approach. Molecular pharmaceutics · 9 Jun 2026 PMID 42260710
Long-Term Clinical Outcomes (3)
  1. Effectiveness and safety of prolonged fenofibrate therapy after the acute phase of hypertriglyceridemic pancreatitis: A long-term retrospective follow-up study. Medicine · 2 Oct 2026 PMID 42826301
  2. Associations between fenofibrate use and sight-threatening diabetic retinopathy in type 2 diabetes: UK real-world evidence. The Journal of clinical endocrinology and metabolism · 7 Sept 2026 PMID 42702803
  3. Fenofibrate add-on therapy improves transplant-free survival in primary biliary cholangitis patients. European journal of gastroenterology & hepatology · 29 May 2026 PMID 42214018
Others — Inflammation and Triglyceride Disorders (2)
  1. Combining bioinformatics and machine learning to analyze and validate sepsis-related cell senescence genes and potential drugs. Renal failure · 31 May 2026 PMID 42219284
  2. A 35-Year-Old Woman With Recurrent Hypertriglyceridemia-Induced Pancreatitis in Pregnancy Managed With Fenofibrate and Plasmapheresis. The American journal of case reports · 28 May 2026 PMID 42204798

By study type

Observational studies and case reports (3)
  1. Effectiveness and safety of prolonged fenofibrate therapy after the acute phase of hypertriglyceridemic pancreatitis: A long-term retrospective follow-up study. Medicine · 2 Oct 2026 PMID 42826301
  2. Fenofibrate add-on therapy improves transplant-free survival in primary biliary cholangitis patients. European journal of gastroenterology & hepatology · 29 May 2026 PMID 42214018
  3. A 35-Year-Old Woman With Recurrent Hypertriglyceridemia-Induced Pancreatitis in Pregnancy Managed With Fenofibrate and Plasmapheresis. The American journal of case reports · 28 May 2026 PMID 42204798
Preclinical: animal, cell and lab studies (6)
  1. Dissolution Enhancement by Binding Agents: A Potential Shortcut to Improving Bioavailability? The AAPS journal · 10 Sept 2026 PMID 42717179
  2. Polymer-free electrospun hydroxypropyl-β-cyclodextrin inserts for sustained ocular delivery of fenofibrate: a novel approach for management of posterior segment ocular disease. International journal of pharmaceutics · 28 Aug 2026 PMID 42665196
  3. Development and Validation of Isocratic RP-UHPLC Method for Assay of Fenofibrate Tablet. Biomedical chromatography : BMC · 28 Jul 2026 PMID 42517867
  4. Data Mining of the Japanese Adverse Drug Event Report Database and Animal Experiments for Assessment of Risks Associated With Pemafibrate. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379788
  5. Visualizing the Spatiotemporal Redistribution of Drugs in Destabilizing Nanoemulsions: A Quantitative Solution 1H NMR Approach. Molecular pharmaceutics · 9 Jun 2026 PMID 42260710
  6. Combining bioinformatics and machine learning to analyze and validate sepsis-related cell senescence genes and potential drugs. Renal failure · 31 May 2026 PMID 42219284
Unclassified: not yet indexed with MeSH (1)
  1. Associations between fenofibrate use and sight-threatening diabetic retinopathy in type 2 diabetes: UK real-world evidence. The Journal of clinical endocrinology and metabolism · 7 Sept 2026 PMID 42702803